Business Context and Reporting Period
Company: Absci Corp (ABSI)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2025
Business Overview: Absci is a clinical-stage biopharmaceutical company utilizing generative AI to design antibody therapeutics. The company operates an "Integrated Drug Creation" platform to advance internally developed programs and partnered drug creation activities. As of the filing date, the company is an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2025 |
Six Months Ended June 30, 2025 |
Six Months Ended June 30, 2024 |
|---|---|---|---|
| Partner Program Revenue | $593 | $1,772 | $2,168 |
| Net Loss | $(30,569) | $(56,915) | $(46,725) |
| Net Loss Per Share (Basic & Diluted) | $(0.24) | $(0.45) | $(0.44) |
| Operating Expenses | $31,986 | $60,894 | $52,387 |
| Cash, Cash Equivalents & Short-Term Investments | $117,500 (as of June 30, 2025) | ||
| Accumulated Deficit | $(566,516) (as of June 30, 2025) |
Liquidity: As of June 30, 2025, the company held $38.0 million in cash and cash equivalents, $16.2 million in restricted cash, and $79.4 million in short-term investments. Management believes current resources are sufficient to meet operating needs for at least the next 12 months.
Material Changes vs. Prior Period
- Revenue Decline: Partner program revenue decreased by 53% ($0.7 million) for the three months ended June 30, 2025, compared to the same period in 2024. For the six-month period, revenue decreased by 18% ($0.4 million). This was driven by the timing of project-based milestones and the mix of ongoing program activity.
- Increased Operating Loss: Net loss increased to $56.9 million for the six months ended June 30, 2025, compared to $46.7 million in the prior year period. The increase was primarily due to higher Research and Development (R&D) expenses.
- R&D Expense Growth: R&D expenses increased by 34% ($9.3 million) year-over-year for the six-month period. This increase was attributable to the advancement of drug creation programs, including external preclinical and clinical development costs, and increased personnel costs.
- SG&A Stability: Selling, general, and administrative expenses remained relatively flat, decreasing slightly by 0% ($0.1 million) for the six-month period compared to the prior year.
Guidance, Outlook, and Risks
Outlook and Pipeline:
- ABS-101 (Inflammatory Bowel Disease): Phase 1 clinical trial dosing initiated in May 2025. An interim clinical readout is anticipated in the second half of 2025. Phase 1b/2a is expected to start in the first half of 2026.
- ABS-201 (Androgenetic Alopecia): Preclinical development is ongoing. An Investigational New Drug (IND) application is anticipated in the first half of 2026, with an interim Phase 1 readout expected in the second half of 2026.
- Capital Needs: The company expects to continue incurring significant expenses to advance internally developed programs and improve its platform. It will need to raise additional capital in the future to fund operations.
Subsequent Events (Post-June 30, 2025):
- Issued 5.1 million shares via "at-the-market" offering for $14.0 million net proceeds.
- On July 28, 2025, sold 16.67 million shares in a public offering at $3.00 per share, raising approximately $46.7 million in net proceeds.
Key Risks:
- Development Uncertainty: Biologic drug development is inherently uncertain; product candidates may fail in preclinical or clinical trials.
- Revenue Concentration: Revenue is highly concentrated; for the six months ended June 30, 2025, three partners represented 100% of total partner program revenue.
- Capital Requirements: The company has an accumulated deficit of $566.5 million and expects to incur losses for the foreseeable future. Failure to raise additional capital could harm operations.
- Regulatory and Political Risk: Disruptions to FDA operations, staffing cuts, or changes in U.S. presidential administration policies could delay regulatory reviews.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $117.5 million cash position against the projected burn rate, considering the recent $60.6 million in post-period financing.
- Revenue Concentration: Assess the risk associated with 100% of partner revenue coming from only three partners.
- Clinical Milestones: Monitor the timing and results of the ABS-101 interim readout (expected H2 2025) and the ABS-201 IND filing (expected H1 2026).
- AMD Collaboration: Review the strategic collaboration with AMD regarding AI optimization and the amortization of the $2.5 million premium paid for the PIPE investment.
- Regulatory Environment: Evaluate potential impacts of FDA staffing changes and new U.S. administration policies on the timeline for IND approvals and clinical trial reviews.